1 / 20

Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention

Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders. Presenter: Theresa Winhusen, Ph.D.

naiya
Download Presentation

Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders Presenter: Theresa Winhusen, Ph.D. June 14, 2006, Pharmacological Treatment of ADHD in Substance-Abusing Adolescents and Adults: New Findings, Research Directions, and Clinical Implications: 3:10 – 3:30

  2. Principal Investigators Principal Investigator • Paula Riggs MD University of Colorado at Denver & Health Sciences Center (UCDHSC) Co-Principal Investigators • Theresa Winhusen PhD • Robert Davies MD, Medical Co LI (UCDHSC)

  3. Background & Significance • 30-50% of adolescents in substance treatment have ADHD • ADHD associated with: • More severe substance abuse • Worse behavior problems • Poorer treatment outcomes

  4. Background & Significance Integrated treatment is considered to be a core drug treatment principle (NIDA, 1999) Recent community treatment survey • < 50% had “dual diagnosis” programs • Of those with dual diagnosis programs: • 43.4% did not offer prescription meds • 37.8% did not offer psychiatric/psychological evaluation Motjabai, 2004

  5. Background & Significance • One RCT targeting ADHD in adolescents with co-occurring SUD • 12 week trial pemoline* n=69, adolescents 13-19 • Similar safety, efficacy for ADHD as in adolescents without SUD • No impact on drug use in the ABSENCE of specific substance treatment Riggs et al 2004 *Schedule 1V psychostimulant

  6. Treatment of ADHD +/- SUD Schedule II psychostimulants, gold standard • Non-scheduled alternatives-- bupropion and atomoxetine-- have lower effect sizes (.5 and .7) OROS-MPH/Concerta • Long acting (12 hours); once daily dosing • Equivalent efficacy to short acting psychostimulants • Controlled delivery system likely reduces abuse potential

  7. Standardized SUD Treatment • Individual Manualized Cognitive Behavioral Therapy (CBT) • Found effective for SUD in adolescents • Individual, not group, due to feasibility • 16 sessions, including up to 3 family sessions

  8. Study Objectives • Primary Objectives • 1a Evaluate safety and efficacy of OROS-MPH vs. Placebo for ADHD in adolescents with SUD • 1b Evaluate impact of treatment of ADHD with OROS-MPH on substance treatment outcomes

  9. Study Design 16-week randomized controlled trial • OROS-MPH (72mg/day) vs placebo • CBT for SUD • Weekly • Outpatient Power • N= 300 to detect low/medium effect size (.4) • 11 study sites

  10. Study Sites • Wave 1 • LRADAC, South Carolina • Synergy, Colorado • STARR, Northern New England • Wave 2 • Operation PAR, Florida • Gateway, Florida • Mountain Manor, Mid-Atlantic • Crittenton, Ohio Valley • St Lukes Roosevelt, Long Island • MHMR of Tarrant County, Texas • Rehab After Work, Delaware Valley • Addiction Medicine Services, Appalachian Tri State

  11. Study Participants Participants • Inclusion • Adolescents (13-18) • DSM IV ADHD • At least one SUD • Exclusion • serious medical illness • bipolar • psychosis • opiate dependence • methamphetamine abuse, dependence • other treatment; psychotropics

  12. Primary Outcome Measures • DSM-IV ADHD Symptom Checklist • Number of Use Days -Substance Use Self-Report using the TLFB

  13. Other Efficacy Measures ADHD • Clinician Global Impression of Improvement (CGI-I) Rating Scale Substance Use Outcomes • Frequency of Drug Use (TLFB) • Urine Toxicology • Proportion of Negative Urines

  14. Safety Measures • Vital Signs/Weight • Pregnancy Test • Adverse Events • Prior/Concomitant Medications • Lab values (urinalysis, CBC, LFTs)

  15. Study Progress • Wave 1 Sites Initiated March 2006 • Wave 2 Site Initiation June-July 2006

  16. Study Progress - Wave 1

  17. Referral Sources - Wave 1

  18. Pre-Screen Ineligibility-Wave 1

  19. Medication Tolerability - Wave 1

  20. Study Timeline & Enrollment Schedule 2006 A/4 M/5 J/6 J/7 A/8 S/9 O/10 N/11 D/12 6 12 18 21 43 65 87 109 131 2007 J/1 F/2 M/3 A/4 M/5 J/6 J/7 A/8 153 175 197 219 241 263 285 307 S/9 O/10 N/11 D/12 2008 J/1F/2 M/3 A/4 Initial projection enrollment completion midpoint enrollment completed 16 wk study completion F/u study completion Study close out, data lock, manuscript preparation

More Related